Publications
Rising Use of Unapproved BPC-157 ("Wolverine Peptide") and Associated Patient-Reported Outcomes Curated from Clinical Notes
Clinical-note surveillance confirmed BPC-157 use in 1,039 patients and found a 33-fold rise in newly documented quarterly users from 2020 to 2026; among patients with a known consumer source, compounding pharmacies and gray-market peptide vendors predominated. Outcome documentation was incomplete and confounded, so this retrospective preprint cannot establish safety or efficacy.
Leading the Conversation in Healthcare AI
Browse nference's publication below
Zepbound
weight loss
October 21, 2026
Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss
While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.
October 20, 2026
Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study
In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.
semaglutide
pregnancy
October 16, 2026
Continuing Semaglutide into the First Trimester of Pregnancy Is Not Associated with Maternal or Newborn Complications in Routine Care
Overall, semaglutide prescribing during pregnancy was not associated with significant differences in maternal or newborn outcomes studied in this routine care setting.
Oral semaglutide
Orforglipron
September 28, 2026
Oral Wegovy is associated with greater early weight loss than Foundayo in propensity matched adult GLP-1 users
In a small subset with 90-day follow-up weights, oral Wegovy was associated with greater early weight loss than Foundayo; comparative safety findings remain exploratory.
Oral semaglutide
Weight-loss response
September 20, 2026
Oral GLP-1 Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions
Greater early weight loss tracked prior weight gain, faster dose escalation, and larger blood-pressure reductions.
BPC-157 Gray-market therapeutics Clinical-note surveillance
September 7, 2026
Rising Use of Unapproved BPC-157 ("Wolverine Peptide") and Associated Patient-Reported Outcomes Curated from Clinical Notes
Clinical-note surveillance confirmed BPC-157 use in 1,039 patients and found a 33-fold rise in newly documented quarterly users from 2020 to 2026; among patients with a known consumer source, compounding pharmacies and gray-market peptide vendors predominated. Outcome documentation was incomplete and confounded, so this retrospective preprint cannot establish safety or efficacy.
Incretin therapies
Kidney biomarkers
September 3, 2026
Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities
The study explored organ-specific biomarker patterns across metabolic therapies.
Neurology
Neuropsychiatry
September 1, 2026
Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss
Across a large observational cohort, higher attained dose was associated with lower later incidence of several neuropsychiatric diagnoses, while dementia rates did not differ significantly.
of 13
© 2026 nference, Inc. All rights reserved.
Your Privacy Choices